China Advanced Therapy Medicinal Products Market Size & Outlook
China advanced therapy medicinal products market, 2018-2030 (US$M)
Related Markets
China advanced therapy medicinal products market highlights
- The China advanced therapy medicinal products market generated a revenue of USD 662.9 million in 2023 and is expected to reach USD 0.0 million by 2030.
- The China market is expected to grow at a CAGR of -100% from 2024 to 2030.
- In terms of segment, gene therapy was the largest revenue generating product in 2023.
Advanced therapy medicinal products market data book summary
| Market revenue in 2023 | USD 662.9 million |
| Market revenue in 2030 | USD 0.0 million |
| Growth rate | -100% (CAGR from 2023 to 2030) |
| Largest segment | Gene therapy |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Gene Therapy, Cell Therapy, Tissue Engineered, Others (Combined ATMPs, for example biodegradable matric or scaffold) |
| Key market players worldwide | Bluebird bio Inc, Novartis AG ADR, UniQure NV, Gilead Sciences Inc, JCR Pharmaceuticals Co Ltd, Vericel Corp, Organogenesis Holdings Inc Class A, Spark Therapeutics, Celgene, Kolon Industries, Medipost, Pharmicell |
Other key industry trends
- In terms of revenue, China accounted for 9.2% of the global advanced therapy medicinal products market in 2023.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Advanced Therapy Medicinal Products Market Scope
Advanced Therapy Medicinal Products Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China advanced therapy medicinal products market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to advanced therapy medicinal products market will help companies and investors design strategic landscapes.
Gene therapy was the largest segment with a revenue share of 52% in 2023. Horizon Databook has segmented the China advanced therapy medicinal products market based on gene therapy, cell therapy, tissue engineered, others (combined atmps, for example biodegradable matric or scaffold) covering the revenue growth of each sub-segment from 2018 to 2030.
In China, nearly 4,535 applications have been submitted for stem cell patents. In this country, R&D in stem cells has gained great importance over the past years. This is indicated through establishment of a major national scientific research plan for stem cell research during the 12th Five-Year Plan.
China is recognized as a global focal point for new therapy development. In current scenario, number of ongoing gene therapy clinical trials in China has surpassed that in the U.S. In 2017, there were around 77 new trials in China and 33 in the U.S.
In March 2019, the Chinese Academy of Sciences launched three stem cell clinic research programs for treatment of gynecological and eye diseases. In recent years, stem cell research has become a key frontier area in China’s healthcare system, as it exhibits potential in treatment of chronic diseases.
Reasons to subscribe to China advanced therapy medicinal products market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China advanced therapy medicinal products market databook
-
Our clientele includes a mix of advanced therapy medicinal products market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China advanced therapy medicinal products market , including forecasts for subscribers. This country databook contains high-level insights into China advanced therapy medicinal products market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China advanced therapy medicinal products market size, by product, 2018-2028 (US$M)
China Advanced Therapy Medicinal Products Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
